CSL Seqirus North America Tiffany Cody Phone: +1 908 370 1863 Email: Tiffany.Cody@seqirus.com Asia Pacific Hamish Walsh Phone: +61 422 424 338 Email: Hamish.Walsh@seqirus.com Global Commercial Development; UK, EMA, Argentina

2024年12月13日 · Why lung cancer is on the increase: Dr Clare Weeden, WEHI, Melbourne How understanding gene switching could lead to new drug classes: Dr Qi Zhang, South Australian immunoGENomics Cancer Institute (SAiGENCI), University of Adelaide

2024年10月24日 · Australia’s newest biotech incubator Jumar Bioincubator has officially opened its doors and revealed the first 16 innovative early-stage ventures to take up residency in its much-awaited Melbourne-based facility at an event officiated by Lord Mayor, Sally Capp AO.

2024年10月24日 · CSL, WEHI, and the University of Melbourne today announced the appointment of an independent operator to oversee and manage the new start-up incubator which will support and grow early-stage Australian biotech companies, providing both …

2024年12月13日 · Seqirus – a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), – has entered into a multi-year influenza research partnership with the University of Liverpool Pandemic Institute.

2024年1月16日 · CSL Behring K.K. (Head Office: Minato-ku, Tokyo; President and Representative Director: Jean-Marc Morange) announces that it has received a manufacturing and marketing approval from the Ministry of Health, Labour and Welfare for “Berinert® S.C. Injection 2000,” a lyophilized human C1-esterase inhibitor concentrate...

Melbourne, Australia – 21 August 2023 – Australia today ushered in a new era in scientific and medical innovation, with Prime Minister of Australia, Anthony Albanese officially opening CSL’s new Global Headquarters and Centre for Research and Development (R&D) in the Parkville biomedical precinct in Melbourne. Part of a A$2 billion infrastructure investment program in …

KING OF PRUSSIA, Pa., Feb. 11, 2024 /PRNewswire/ -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced top-line results from the Phase 3 AEGIS-II trial evaluating the efficacy and safety of CSL112 (apolipoprotein A-I [human]) compared to placebo in reducing the risk of major adverse cardiovascular events (MACE) in patients following an acute myocardial infarction (AMI).

2022年11月2日 · Pipeline advancements and investment in innovation and disruptive technologies to help fuel sustainable, profitable growth for CSL's three businesses, CSL Behring, CSL Seqirus and CSL Vifor, in...

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Agreement announced on the Australian Securities Exchange and SIX Swiss Exchange on 14 December 2021 Cash offer at US$179.25 per share Offer equivalent...